About us
It is the shared vision of every member of Centus Biotherapeutics to enable a world where high quality and affordable biologics are made readily available to patients.
Founded in 2015, Centus Biotherapeutics is a joint venture between AstraZeneca, a global pharmaceutical leader, and Fujifilm Kyowa Kirin Biologics (FKB), a Japanese biopharmaceutical company focused on biosimilar development. With the unique coupling of world class biologics expertise, global commercial infrastructure and deep biosimilar development experience, Centus Biotherapeutics is well positioned to win the trust of doctors and serve the needs of patients worldwide.
back to topTeam and Values
Centus Biotherapeutics has assembled a truly global team with world class experience from around the world. From different continents around the world, the team works seamlessly and around the clock to ensure product critical quality attributes are highly similar to reference product, manufacturing quality is tightly controlled and patients are recruited and treated with care.
At the heart of Centus Biotherapeutics is a common set of values that drives us towards this vision and mission:
Drive for excellence
Responsible/Accountable
Teamwork
Resilience
Entrepreneurial
Openness and transparency
Understanding and respect each other
Trust
Integrity
Efficiency and effectiveness
back to top
Investor
Centus Biotherapeutics is happy to have the breadth and depth of support, including capabilities, experience, resources and capital, from the largest pharmaceutical companies in the world.
Fujifilm Kyowa Kirin Biologics was established by FUJIFILM Corporation (President: Kenji Sukeno; hereinafter “Fujifilm”) and Kyowa Hakko Kirin Co., Ltd. (President and CEO: Nobuo Hanai, hereinafter “Kyowa Hakko Kirin”) on March 27, 2012 as a company for developing, manufacturing and marketing biosimilars. For more information please visit: http://fujifilmkyowakirin-biologics.com/en/index.html
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.
back to top